Veyx-Pharma GmbH develops, manufactures and sells veterinary pharmaceuticals, feed, animal care products and nutritional supplements and manages drug registrations and new drug approvals. The company is based in Schwarzenborn; revenue rose in 2023 to 23,238.82 TEUR from 22,610.64 TEUR in 2022 (increase of 2.78 %), with domestic sales up +0.35 % and exports up +6.07 %. The average workforce during the year was 61 employees and the company holds participations in subsidiaries in Slovakia, Bulgaria, the Netherlands and Poland (ownership stakes up to 100%). All 2023 investments were financed from cash flow; bank balances amounted to 3,912,603.06 EUR as of 31.12.2023 and there were no bank liabilities.
Herstellung und Vertrieb von chemisch-pharmazeutischen Produkten und Futtermitteln, die Verwaltung und Auswertung von Arzneimittelregistrierungen und Arzneimittelneuzulassungen, Warenzeichen, Patenten und arzneimittelrechtlichen Mitvertriebsrechten sowie das Betreiben von Arzneimittelneuzulassungen
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 4305 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Silke Engl | Geschäftsführer(in) | Melsungen |
| Armin Heß | Geschäftsführer(in) | Schwarzenborn |
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 4305 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€12.1M2 | €1,992,788 | €19,754,004 | — |
| 2023 | Rohergebnis€11.8M2 | €2,468,601 | €17,621,505 | — |
| 2022 | Rohergebnis€11.4M2 | €2,310,307 | €16,131,246 | — |
| 2021 | Rohergebnis€11.5M2 | €2,237,463 | €14,941,178 | — |
| 2020 | Rohergebnis€11.3M2 | €2,022,133 | €13,113,442 | — |
| 2019 | Rohergebnis€11.2M2 | €2,302,709 | €11,110,351 | — |
| 2018 | Rohergebnis€10.8M2 | €2,096,088 | €12,259,291 | — |
| 2017 | Rohergebnis€10.5M2 | €2,087,827 | €10,244,568 | — |
| 2016 | Rohergebnis€8.9M2 | €1,355,066 | €8,020,203 | — |
| 2015 | Rohergebnis€8.6M2 | €1,443,984 | €7,078,048 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 4305 (as of 31 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,569,092 | 91.9% |
| Depreciation | €389,656 | 7.8% |
| Interest & Similar | €12,117 | 0.2% |
